Trulieve Cannabis Corp, a health care holding company based in Quincy, United States, operates within the pharmaceutical sector, focusing on the cultivation, possession, sale, and distribution of medical cannabis products. These products are specifically designed to alleviate symptoms associated with serious medical conditions, including cancer. As a holding company, Trulieve Cannabis Corp oversees these activities through its subsidiaries.
The company is listed on the OTC Bulletin Board, trading under the currency of USD. As of November 11, 2025, the close price of Trulieve Cannabis Corp’s stock was recorded at $6.88. Over the past year, the stock has experienced significant fluctuations, reaching a 52-week high of $9.95 on August 27, 2025, and a 52-week low of $3.02 on April 6, 2025. The market capitalization of the company stands at approximately $1.33 billion USD.
Financially, Trulieve Cannabis Corp has a price-to-earnings (P/E) ratio of -10.283, indicating that the company is currently not generating profits. This negative P/E ratio reflects the challenges faced by the company in achieving profitability, which is not uncommon in the rapidly evolving cannabis industry.
Trulieve Cannabis Corp’s operations are centered around providing medical cannabis solutions to patients with serious medical conditions. The company’s commitment to alleviating symptoms through its products underscores its role in the health care sector, particularly within the realm of alternative and complementary medicine.
For more information about Trulieve Cannabis Corp and its offerings, interested parties can visit their official website at www.trulieve.com . The company continues to navigate the complexities of the cannabis market, aiming to expand its reach and impact within the health care industry.
